Mesothelioma Patients Wanted For New Clinical Trial, Backed By the National Cancer Institute

The National Cancer Institute (NCI) is looking for malignant mesothelioma patients interested in participating in a new clinical trial. The clinical trial introduces medications combined with genetic mutations in attempt to help treat the disease in a new way that experts feel will show a lot of promise for mesothelioma patients everywhere.

According to NCI, the clinical trial is something that has never been attempted before and has the potential to not only treat those participating, but also change the way mesothelioma patients are treated for mesothelioma in the future. Per Dr. Doug Lowy, NCI’s acting director, if the treatment is successful in the clinical trial, it may become a prescribed medication to help all mesothelioma patients.

“It is a unique, groundbreaking trial. It is the first study in oncology that incorporates all of the tenets of precision medicine. There are no other cancer clinical trials of this size and scope that truly bring the promise of targeted treatment to patients whose cancers have specific genetic abnormalities.”

Numerous medications will be used in the clinical trial, some of which are already approved by the U.S. Food and Drug Administration (FDA), and some of which are new and experimental.

How to Enroll in the New Clinical Trial

The clinical trial, known as the Molecular Analysis for Therapy Choice (MATCH) has a two-step enrollment process. The first step is the screening process in which a patient will undergo a DNA sequencing biopsy in order to detect the genetic abnormality. If one of the medications detects the genetic abnormality, the patient is then eligible to move onto the next step of the clinical trial screening process.

The second step consists of finding people with rare types of cancers, including those with mesothelioma. The clinical trial hopes to find at least 1,000 people with rare types of cancers, with a portion of this number being those with pleural or peritoneal mesothelioma.

If the patient is matched, they will be assigned to one of the sites where the clinical trial will be conducted. NCI estimates that over 2,000 sites will open for the first part of the new clinical trial. Dr. Barbara Conley, an associate director of the program, indicates that clinical trial aims to detect tumors that can be sequenced.

“What we’re trying to do is sequence their tumor for various cancer drivers. If they have that driver, they will be able to get the drug that was chosen to attack that driver.”

Is There a Cost to Participate in the New Clinical Trial?

Accepted participants of aren’t required to pay anything for the clinical trial, including any medications used. The NCI backs the costs of the majority of the clinical trial, which is one of the many benefits of these types of trials being sponsored by NCI.

The only costs participants would be responsible for is any medications or other measures needed to handle any of the side effects that the treatments cause.

If you think you fit the profile for the new study, and are interested in participating, contact the NCI directly at 1-800-4-CANCER. If you have any questions or need assistance, feel free contact us directly at 800-694-4856.

Additional Information and Resources for Mesothelioma Patients

If you or a loved one were diagnosed with mesothelioma or any other illness due to asbestos exposure, you may be entitled to substantial compensation. We invite you to fill out our contact form today to get free brochures from the top mesothelioma lawyers in your area. For more than 20 years, we’ve been helping families successfully connect with the best mesothelioma attorneys. With over $30 billion currently in asbestos trust funds, now is the right time to take the first step in determining what you may qualify for.

FREE Financial Compensation Packet

Free Next Day Shipping
There is a time limit - ACT NOW
  • Info on law firms that will recover your highest compensation
  • Learn how to get paid in 90 days
  • File for your share of $30 billion in trust funds
  • This field is for validation purposes and should be left unchanged.